Navigation Links
Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010
Date:2/24/2011

cals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.

Safe Harbor StatementCertain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

PAR PHARMACEUTICAL COMPANIES, INC.CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Data)(Unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,December 31,December 31,2010200920102009Revenues:Net product sales

$217,483$285,094$980,631$1,176,427Other product related revenues

9,5455,22728,24316,732Total revenues

227,028290,3211,008,8741,193,159Cost of goods sold

131,760198,983635,343859,206Gross margin

95,26891,338373,531333,953Operating exp
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Nortek Security ... NTK ) and a leader in the ... today announced it acquired mobile personal emergency response ... held Numera, Inc. Headquartered in ... easily implemented, mobile PERS products and cloud-based software ...
(Date:6/30/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... today announced it has submitted its fifth abbreviated new ... Administration (FDA) of 2015, which brings the Company,s total ... to twenty-seven. Jason Grenfell-Gardner , President ... current pipeline of twenty-seven submissions, exclusive of our four ...
(Date:6/30/2015)... new way for people to keep their family safe, while ... is being introduced to the world via an Indiegogo ... $70,000, which needs to be raised in order to bring ... device was inspired by the many scenarios people face in ... day. While medical alert bracelets have been around for years, ...
Breaking Medicine Technology:Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 2Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 3Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 4IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015 2Amyko Propels Medical Alert Bracelets Into the Modern Era 2
... , DENVER , Feb. 11 ... and marketer of diagnostic test kits, today filed its 2nd quarter ... the company,s revenues slightly declined during the quarter but slightly increased ... of the results highlighted by the report are as follows: , ...
... MOUNTAIN VIEW, Calif. , Feb. 11 Alexza Pharmaceuticals, ... & Drug Administration has accepted the AZ-004 NDA for filing and ... of October 11, 2010 .  Alexza filed the AZ-004 NDA ... for the rapid treatment of agitation in patients with schizophrenia or ...
Cached Medicine Technology:Corgenix Reports Second Quarter Fiscal 2010 Financial Results 2Corgenix Reports Second Quarter Fiscal 2010 Financial Results 3Corgenix Reports Second Quarter Fiscal 2010 Financial Results 4Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 2Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 3
(Date:6/30/2015)... ... June 30, 2015 , ... After many ... , finally its here, http://www.express-glasses.com is proud to announce its collaboration ... ask about shipping with DHL Express when calling or visiting the express glasses ...
(Date:6/30/2015)... ... June 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier ... and added a new CEO, Mr. Darold Francis. The changes will help enhance the ... oils that customers have come to know and respect for over eight years. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice ... family of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... News Digest discussed the advantages that fat transfer procedures had over breast ... using fat transfer techniques create breasts that “look and feel natural,” have increased ...
(Date:6/30/2015)... ... 2015 , ... Board certified otolaryngologist Dr. Marcelo B. Antunes ... , Dr. Antunes is a fellowship trained facial plastic surgeon with ... to performing cosmetic and reconstructive surgery on the face, he enjoys treating patients ...
Breaking Medicine News(10 mins):Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3
... , Salad Bar to Be Donated to ... , , WASHINGTON, Aug. 19 The ... bar at its Fresh Festival event, September 9, in the Cannon House ... salad bar, stocked with fresh fruits and vegetables, will underscore the need ...
... , , NEW YORK, Aug. ... point-of-care digital signage network into major U.S. markets, including Detroit, Miami, ... demand for HMN,s services by healthcare providers and advertisers. Installations in ... markets is slated for the second half of 2009. HMN,s largest ...
... experts say , WEDNESDAY, Aug. 19 (HealthDay ... with the drug letrozole (Femara) increases survival after surgery ... confirms. , Both letrozole and tamoxifen have been used ... with hormone receptor-positive cancer, but whether one drug is ...
... , , , ... and BRISBANE, Calif., Aug. 19 Roche (SIX: ROG.VX; RO.S, OTCQX: ... that the first patient has been dosed in a Phase 2b ... in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). ...
... (August 19, 2009) Using a novel robot-assisted endoscopic ... of Medicine in Seoul, Korea, has successfully treated 200 ... which has several technical and cosmetic benefits that the ... the August issue of the Journal of the ...
... paraffin, suggest beeswax instead , WEDNESDAY, Aug. 19 (HealthDay ... ambiance, fragrance and light, may also contribute to air ... made from petroleum, are a source of known human ... to be presented Wednesday at the American Chemical Society,s ...
Cached Medicine News:Health News:United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 2Health News:United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 3Health News:Health Media Network Expands to New Markets 2Health News:Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 2Health News:Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 3Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 2Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 3Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 4Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 5Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 6Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 7Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 8Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 9Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 10Health News:New robot-assisted surgical method found successful for treatment of thyroid cancer 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line of flowmeters, available ... are all available in a variety of calibrations to ... dials specific to the gas in use, the Amvex ... colors replace the U with I. For Power Take-Off ...
Medicine Products: